SCM
SNDX icon

Stonepine Capital Management’s Syndax Pharmaceuticals SNDX Stock Holding History

Stonepine Capital Management’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-37,200
Closed -$572K – 83
2025
Q3 		$572K Sell
37,200
-55,700
-60% -$729K 0.47% 38
2025
Q2 		$870K Buy
+92,900
New +$1.02M 0.85% 30
2018
Q3 		– Sell
-198,373
Closed -$1.39M – 35
2018
Q2 		$1.39M Buy
+198,373
New +$1.95M 0.85% 20

Other funds holding SNDX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Stonepine Capital Management's SNDX Position: Q4 2025 in Review

Stonepine Capital Management sold out of Syndax Pharmaceuticals (SNDX) in Q4 2025, closing a stake of 37,200 shares — an estimated $572K sold.

Stonepine Capital Management first reported a position in SNDX in Q2 2018 and held it in 3 quarters. The position peaked at $1.39M in Q2 2018. 229 funds tracked by Wall St. Rank hold SNDX as of Q4 2025.

  • Stonepine Capital Management reported no remaining Syndax Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Stonepine Capital Management sold 37,200 Syndax Pharmaceuticals shares in Q4 2025, an estimated $572K.
  • Stonepine Capital Management first reported a position in Syndax Pharmaceuticals in Q2 2018 and held it in 3 quarters.
  • Stonepine Capital Management's Syndax Pharmaceuticals position peaked at $1.39M in Q2 2018.
  • 229 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q4 2025.

Based on Stonepine Capital Management's 13F filing for Q4 2025, filed 13 Feb 2026.